<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262093</url>
  </required_header>
  <id_info>
    <org_study_id>PRIMIMULTI-HMO-CTIL</org_study_id>
    <nct_id>NCT00262093</nct_id>
  </id_info>
  <brief_title>Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence</brief_title>
  <official_title>Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      The reason for having a higher incidence of preeclampsia in primiparas may involve
      angiogenesis imbalance in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primiparity is one of the main risk factors for having preeclampsia during pregnancy.
      Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule
      involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of
      sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic
      patients.

      We intend to check the angiogenesis profile of primiparas as compared to multiparas.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional, Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pre-Eclampsia</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Every delivery

        Exclusion Criteria:

          -  Preeclampsia or pregnancy induced hypertension
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuval Bdolah, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah-Hebrew University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuval Bdolah, MD, MSc</last_name>
    <phone>972-2-5844111</phone>
    <email>ybdolah@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lemberg, PhD</last_name>
    <phone>972-2-6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Yuval Bdolah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2005</study_first_submitted>
  <study_first_submitted_qc>December 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <last_update_submitted>March 19, 2007</last_update_submitted>
  <last_update_submitted_qc>March 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2007</last_update_posted>
  <keyword>preeclampsia</keyword>
  <keyword>sFlt1</keyword>
  <keyword>PlGF</keyword>
  <keyword>parity</keyword>
  <keyword>angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

